A Double-Blind, Randomised, Vehicle-Controlled Phase 1b Study to Evaluate the Safety and Pharmacokinetics of GDD3898 Topical Gel in Over-weight or Obese Subjects with Presumed Nonalcoholic Fatty Liver Disease (NAFLD)
Latest Information Update: 11 Mar 2022
At a glance
- Drugs GDD 3898 (Primary)
- Indications Weight gain
- Focus Adverse reactions; Proof of concept
Most Recent Events
- 11 Mar 2022 Status changed from planning to not yet recruiting.
- 12 Mar 2020 New trial record